正交试验法优化美洲大蠊糖蛋白的提取工艺

目的：优选美洲大蠊糖蛋白的提取工艺条件。方法：在单因素的基础上采用L9（34）正交试验法,以美洲大蠊多糖和蛋白质含量、干膏得率为评价指标,考察溶剂量、煎煮次数、煎煮时间,并结合综合评分的方法优选美洲大蠊糖蛋白的提取工艺。结果：最佳提取工艺为：12倍溶剂量,1 h/次,提取3次。结论：优化所得的提取工艺可最大限度的保留有效成分,该提取工艺稳定可行、科学合理,适合于工业化大生产。     

Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies

1. Download : Download high-res image (99KB)
2. Download : Download full-size image

     

Mucosal glucosamine synthetase activity in inflammatory bowel disease

Abnormalities in colonic glycoprotein synthesis have been implicated in the pathogenesis of ulcerative colitis and Crohn's disease. Glucosamine synthetase is the rate-limiting step in the biosynthesis of gastrointestinal glycoprotein and has been measured in control subjects (N=23) and patients with ulcerative colitis (N=26) or Crohn's disease of the colon (N=20) classified according to the macroscopic status of the rectum. Glucosamine synthetase activity was relatively constant around the normal colon but lower levels were found in the terminal ileum. In ulcerative colitis, glucosamine synthetase activity was similar to controls (24.0±1.9) mmol/g wet (wt/hr) irrespective of disease activity (quiescent:N=13, =27.3±1.9; activeN=16, =26.2±2.3). Rectal glucosamine synthetase activity was normal in the presence of active Crohn's proctocolitis (29.4±3.1) but raised in patients with Crohn's colitis and rectal sparing (37.2±4.9P<0.02). Glucosamine synthetase activity was strongly influence by the degree of epithelial preservation.     

甘薯的抗家兔主动脉粥样硬化形成作用

为观察甘薯糖蛋白对家兔实验性动脉粥样硬化形成的影响并探讨其可能的发病机制。将 4 0只新西兰白兔随机分为正常组 (饲以普通饲料 )、高脂组 (饲以胆固醇饲料 )、低剂量甘薯糖蛋白 (简称低剂量 )组 [饲以胆固醇饲料 +糖蛋白 0 .0 6g/ (kg·d) ]和高剂量甘薯糖蛋白 (简称高剂量 )组 [饲以胆固醇饲料 +糖蛋白 0 .1g/ (kg·d) ]。在实验开始时和 12周时分别检测血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、超氧化物歧化酶和丙二醛含量。第 12周末处死动物 ,行主动脉病理形态学观察。结果发现 ,实验前各组血清检测指标无明显差异。实验 12周 ,高脂组、低剂量组和高剂量组血清总胆固醇、甘油三酯、低密度和高密度脂蛋白胆固醇以及丙二醛含量均高于或明显高于正常组 (正常组、高脂组、低剂量组和高剂量组的总胆固醇分别为 1.2 7± 0 .73、2 0 .2 6± 0 .13、15 .2 7± 0 .83和 11.2 8± 1.6 2mmol/L ;甘油三酯分别为 0 .85± 0 .18、1.85± 0 .35、1.71± 0 .2 8和 1.5 1± 0 .11mmol/L ;低密度脂蛋白胆固醇分别为 0 .5 0± 0 .0 7、18.99± 2 .6 5、14 .2 7± 3.0 4和 12 .13± 3.5 6mmol/L ;高密度脂蛋白胆固醇分别为 0 .5 4± 0 .11、0 .75± 0 .10、0 .81± 0 .0 6和 0 .94± 0 .0     

不同磷脂肽段诱导的实验性自身免疫性脑脊髓炎模型病理特征多样性的研究

目的:探索是否不同磷脂肽段可以诱导Lewis大鼠产生不同的病理学表现。方法:采用髓鞘碱性蛋白82-99(MBP82-99)、MBP68-86、髓鞘少突胶质细胞糖蛋白35-55(MOG35-55)免疫Lewis大鼠,每天进行神经功能评分。免疫后取各组大鼠大脑、小脑、脑干和脊髓组织,观察炎性细胞浸润部位和浸润程度、有无脱髓鞘和轴索损害。结果:MBP68-86和MBP82-99两组大鼠的大脑、脑干、小脑和脊髓组织均有炎性细胞浸润,脊髓炎症程度重于其他部位;MBP68-86和MBP82-99诱导的脊髓炎症程度无统计学差异;MOG35-55组大鼠仅脊髓组织受累,且炎症程度明显低于MBP组,其余各组未见炎性细胞浸润。各组大鼠神经组织均未见脱髓鞘和轴索受累。结论:不同磷脂肽段诱导Lewis大鼠神经组织炎性细胞浸润的分布和程度不同。     

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art

Platelets have been shown to play an important role in the pathogenesis of atherosclerosis, acute coronary syndromes, and ischemic complications after percutaneous coronary intervention. Fibrinogen binding via platelet surface glycoprotein (GP) IIb/IIIa receptors constitutes the "final pathway" in platelet aggregation leading to thrombus formation. The GP IIb/IIIa receptor inhibitors, a new class of antiplatelet agents that have emerged in recent years, show great promise in reducing complications of coronary angioplasty and acute coronary syndromes. This review will examine the biology of platelet GP IIb/IIIa receptors, the various classes of GP IIb/IIIa receptor antagonists, the results of the latest clinical trials, and their implications in current clinical practice.     

枸橼酸咖啡因对新生大鼠缺氧缺血性脑损伤后髓鞘碱性蛋白的影响

目的研究枸橼酸咖啡因对新生大鼠缺氧缺血性脑损伤(HIBD)后脑白质髓鞘碱性蛋白(MBP)表达的影响及其相关机制。方法将48只7日龄Sprague-Dawley新生大鼠随机分为假手术组、HIBD组和枸橼酸咖啡因干预组,每组16只。左侧颈总动脉结扎并缺氧(80 m L/L氧气和920 m L/L氮气)2 h制作HIBD模型;假手术组仅分离左侧颈总动脉,不行结扎及缺氧处理;干预组在缺氧缺血前、缺氧缺血后0、24、48、72 h给予枸橼酸咖啡因(20 mg/kg)腹腔注射,HIBD组分别在同一时间点以等量生理盐水行替代腹腔注射。各组大鼠于12日龄处死,采用免疫组织化学法检测左侧脑皮层下白质MBP的表达;实时荧光定量逆转录聚合酶链式反应技术(Real-time PCR)检测各组大鼠左侧脑组织腺苷A1受体(A1R)和A2a受体(A2a R)m RNA的含量。结果 HIBD组左侧脑皮质下白质MBP表达较假手术组明显减少(P0.05),干预组较HIBD组MBP表达增多,但仍低于假手术组(P0.05);HIBD组A1R m RNA较假手术组显著上调(P0.05),干预组A1R m RNA较HIBD组显著下降(P0.05)。结论枸橼酸咖啡因能减轻缺氧缺血后新生大鼠脑白质损伤,这种保护作用可能与下调腺苷A1R表达有关。     

Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty.

The objective of this study was to evaluate the effectiveness of two different closure devices in patients undergoing rescue percutaneous coronary intervention (PCI) using IIb/IIIa inhibitors and to compare it with patients undergoing elective PCI. One hundred sixty-two patients undergoing rescue PCI treated with IIb/IIIa inhibitors underwent vascular access site closure (6 Fr Perclose, n = 92, or 6 Fr Angioseal, n = 70). Vascular complications were compared with a sex- and age-matched group (n = 100) of patients undergoing manual compression after sheath removal and a similar group of patients undergoing elective PCI (n = 196). The incidence of access site complications was not significantly different between the three groups undergoing rescue PCI and was not higher than in patient receiving GP IIb/IIIa inhibitors without fibrinolysis (RR = 0.95; 95% CI = 0.88-1.01). In patients undergoing rescue PCI and receiving IIb/IIIa inhibitors, closure devices allow early sheath removal and are associated with similar outcomes compared with manual compression and elective PCI regardless of the type of closure device used.     

A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity

The varicella-zoster virus (VZV) Oka vaccine strain (vOka) is highly efficient and causes few adverse events; therefore, it is used worldwide. We previously constructed recombinant vOka (rvOka) harboring the mumps virus gene. Immunizing guinea pigs with rvOka induced the production of neutralizing antibodies against the mumps virus and VZV.Here, we constructed recombinant vOka viruses containing either the respiratory syncytial virus (RSV) subgroup A fusion glycoprotein (RSV A–F) gene or RSV subgroup B fusion glycoprotein (RSV B–F) gene (rvOka-RSV A–F or rvOka-RSV B–F). Indirect immunofluorescence and Western blot analyses confirmed the expression of each recombinant RSV protein in virus-infected cells. Immunizing guinea pigs with rvOka-RSV A–F or rvOka-RSV B–F led to the induction of antibodies against RSV proteins. These results suggest that the current varicella vaccine genome can be used to generate custom-made vaccine vectors to develop the next generation of live vaccines.